Rilzabrutinib ITP denied as not FDA-approved for this use by Cigna?

Cigna's specific coverage criteria for rilzabrutinib itp are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Denies Rilzabrutinib for ITP as Not FDA-Approved

This denial type signals that Cigna believes the requested use of rilzabrutinib falls outside the scope of current FDA approval — either because the drug itself does not yet carry FDA approval for ITP, or because the specific indication or patient population described in the authorization request does not match the approved labeling. It can also occur due to administrative mismatch between how the request was coded and what is on file with the FDA.

Note: Drug approval status changes. Before proceeding, confirm the current FDA approval status for rilzabrutinib in ITP directly at the FDA's Drugs@FDA database or through your prescriber. If approval has been granted since the denial was issued, the denial basis may already be moot and a corrected resubmission may resolve it quickly.

## Why This Denial Is Appealable

Even where a drug lacks full FDA approval for the exact indication, many plans are required to cover off-label use supported by recognized compendia or clinical evidence — particularly for serious or chronic conditions. If the drug does carry FDA approval for ITP, then the denial is factually incorrect and must be overturned. Either way, you have appeal rights.

Federal rights that apply: - ACA §2719 / ERISA §503 full-and-fair internal appeal with written clinical rationale. - External review by an independent review organization after internal appeal failure; the window is generally up to approximately four months from the denial notice — verify on your Explanation of Benefits. - Expedited review where standard timelines would jeopardize health.

## Your Appeal Process and Timeline

1. Verify the current FDA label for rilzabrutinib and print the relevant indication language. 2. If FDA-approved for ITP: attach the label excerpt to a letter of appeal pointing out the factual error in the denial. 3. If used off-label: document support from recognized sources (ASH guidelines, peer-reviewed literature) and confirm whether your plan's off-label coverage policy applies. 4. File the internal appeal, then request external review if denied.

## Documentation to Gather

• FDA prescribing information: current label with approval date and approved indication text.
• Diagnosis documentation: confirming the indication matches what is approved or recognized in guidelines.
• Prescriber letter: addressing the approval status question directly and citing clinical evidence or compendia support.
• Plan language on off-label coverage: your Summary Plan Description section on experimental or off-label treatments.

## Criteria-Mapping Structure

Place the FDA approval language next to Cigna's denial language and map each concern to a direct factual response. If the drug is approved, the table is brief. If off-label, map each recognized-compendia or guideline citation to Cigna's off-label coverage criteria. Specificity matters — generic appeals are easily dismissed.